Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | CTSA | P10619 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2604628 | 0.95 | AKR1C3 (0.46) | AKR1C3AKR1C2PTGS2FAAH | |
| SCHEMBL18472419 | 0.91 | PTGS1 (0.46) | AKR1C3AKR1C2PTGS2FAAHTHRB | |
| SCHEMBL2604649 | 0.88 | FFAR4 (0.41) | AKR1C3AKR1C2PTGS2CTSATHRB | |
| SCHEMBL9607903 | 0.88 | THRB (0.44) | AKR1C3AKR1C2PTGS2THRBESR1 | |
| SCHEMBL9607789 | 0.87 | THRB (0.45) | THRBESR1ESR2 | |
| SCHEMBL9607850 | 0.86 | THRB (0.43) | AKR1C3AKR1C2PTGS2THRBESR1 | |
| SCHEMBL9607784 | 0.84 | ESR1 (0.39) | AKR1C3AKR1C2CTSATHRBESR1 | |
| SCHEMBL3438597 | 0.84 | ERN1 (0.39) | AKR1C3AKR1C2PTGS2CTSATHRB | |
| SCHEMBL24411805 | 0.82 | HSD17B1 (0.38) | AKR1C3AKR1C2THRBESR1ESR2 | |
| SCHEMBL18773562 | 0.81 | CYP2C19 (0.53) | AKR1C3AKR1C2PTGS2CTSATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394468-B2 | Polymerizable compound and liquid crystal composition including it | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-8394468-B2 | Polymerizable compound and liquid crystal composition including it | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20120092608-A1 | POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL COMPOSITION INCLUDING IT | JNC PETROCHEMICAL CORPORATION (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120092608-A1 | POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL COMPOSITION INCLUDING IT | JNC PETROCHEMICAL CORPORATION (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120092608-A1 | POLYMERIZABLE COMPOUND AND LIQUID CRYSTAL COMPOSITION INCLUDING IT | KLK3, PDE7A, FZD7 | AKR1C3 3550/4885AKR1C2 3486/4885PTGS2 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.